Horizon Discovery Ltd. signs a commercial agreement with AstraZeneca UK Ltd.
Horizon Discovery (Horizon) has signed a commercial agreement to supply leading global Pharma company AstraZeneca with its isogenic cell-lines. The financial terms of the deal remains confidential but involve payment of up-front and milestone payments.
Chris Torrance, Horizon CEO says: “We are delighted to have AstraZeneca as an early-adopter of our cell-lines and look forward to a long and fruitful relationship with AstraZeneca”.